# Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

> **NCT06989840** · PHASE1 · RECRUITING · sponsor: **Sagimet Biosciences Inc.** · enrollment: 128 (estimated)

## Conditions studied

- Acne

## Interventions

- **DRUG:** TVB-3567
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06989840
- **Lead sponsor:** Sagimet Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-03
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06989840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06989840, "Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06989840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*